Patents by Inventor David Glass

David Glass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210127945
    Abstract: A food and beverage preparation system and method for the precision wiping of plates and glassware in restaurants and bars including one or more cylindrically shaped fiber rolls having flat ends and a sanitary dispensing means for the one or more cylindrically shaped fiber rolls. A dry use method involves removing a cylindrical shaped fiber roll from a sanitary dispenser, grasping the fiber roll in a manner conducive to precision wiping, wiping a specific area of a plate or other surface and discarding the cylindrical shaped fiber roll when done. A wet use method involves wetting or dampening the cylindrical shaped fiber rolls in specialized liquids and grasping the fiber roll in a manner conducive to precision wiping, wiping a specific area of a plate or other surface and discarding the cylindrical shaped fiber roll when done.
    Type: Application
    Filed: October 30, 2020
    Publication date: May 6, 2021
    Applicant: Eleven Stone, LLC
    Inventors: David Glass, Mark Glassman
  • Publication number: 20210030741
    Abstract: The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.
    Type: Application
    Filed: November 21, 2019
    Publication date: February 4, 2021
    Inventors: David Glass, Joan Mannick, Leon Murphy
  • Patent number: 10708731
    Abstract: The provision of dual mode services is facilitated. Access to the dual mode services is controlled by associating a mobile device to an access point. Subscribers are required to provide valid geographical addresses for access points associated with the mobile devices prior to provision of service. Consequently, physical addresses are necessarily available for emergency services (e.g., E911). Mobile devices are restricted to specific access points based upon the access point identifiers automatically provided during initialization of service and maintained for authorization purposes.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 7, 2020
    Assignee: AT&T MOBILITY II LLC
    Inventors: David Glass, Adnan Abu-Dayya
  • Patent number: 10576076
    Abstract: The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 3, 2020
    Assignee: Novartis AG
    Inventors: David Glass, Joan Mannick, Leon Murphy
  • Patent number: 10568947
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 25, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20200054742
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Application
    Filed: March 22, 2019
    Publication date: February 20, 2020
    Inventors: Joan Mannick, David Glass, Leon Murphy
  • Publication number: 20190233034
    Abstract: An unmanned and self-powered vehicle or Towable Autonomous Dray (TOAD) may follow a vehicle and tow a trailer, haul a load, and/or recharge a pilot vehicle. The TOAD may be semi-autonomous and may attach to a pilot vehicle by an electronic identification. Further, wireless charging of the pilot vehicle may be provided by the TOAD. Smart trailer brakes, electric trailer axles, and a mechanically coupled tow vehicle may be provided by the TOAD in combination with additional units. A smart trailer controller may include a smart head unit and a smart tail unit in a trailer that may offer trailer security and increased safety. A smart trailer brake controller on the pilot vehicle and a smart module on the trailer may be applied where no unmanned vehicle is employed, such as, in a classic pick-up/trailer combination.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Applicant: Vieletech Inc.
    Inventors: Matthew Viele, David Glass
  • Patent number: 10357514
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Publication number: 20190215666
    Abstract: The provision of dual mode services is facilitated. Access to the dual mode services is controlled by associating a mobile device to an access point. Subscribers are required to provide valid geographical addresses for access points associated with the mobile devices prior to provision of service. Consequently, physical addresses are necessarily available for emergency services (e.g., E911). Mobile devices are restricted to specific access points based upon the access point identifiers automatically provided during initialization of service and maintained for authorization purposes.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 11, 2019
    Inventors: David Glass, Adnan Abu-Dayya
  • Patent number: 10286069
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Joan Mannick, David Glass, Leon Murphy
  • Patent number: 10278026
    Abstract: The provision of dual mode services is facilitated. Access to the dual mode services is controlled by associating a mobile device to an access point. Subscribers are required to provide valid geographical addresses for access points associated with the mobile devices prior to provision of service. Consequently, physical addresses are necessarily available for emergency services (e.g., E911). Mobile devices are restricted to specific access points based upon the access point identifiers automatically provided during initialization of service and maintained for authorization purposes.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: April 30, 2019
    Assignee: AT&T Mobility II LLC
    Inventors: David Glass, Adnan Abu-Dayya
  • Patent number: 10174095
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: January 8, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • Publication number: 20180369370
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 27, 2018
    Inventors: Joan MANNICK, David GLASS, Leon MURPHY
  • Publication number: 20180334490
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
    Type: Application
    Filed: December 2, 2015
    Publication date: November 22, 2018
    Inventors: Jennifer Brogdon, Gregory Beatty, David Glass, Carl H. June, Joan Mannick, Michael Milone, Leon Murphy, Gabriela Plesa, Huijuan Song, Qilong Wu
  • Publication number: 20180289694
    Abstract: The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.
    Type: Application
    Filed: May 20, 2016
    Publication date: October 11, 2018
    Inventors: David Glass, Joan Mannick, Leon Murphy
  • Patent number: 10004803
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, for example, with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Joan Mannick, David Glass, Leon Murphy
  • Publication number: 20180118834
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Application
    Filed: January 15, 2016
    Publication date: May 3, 2018
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20180066061
    Abstract: The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Application
    Filed: September 28, 2017
    Publication date: March 8, 2018
    Inventors: Dimitris Papanicolaou, Ronenn Roubenoff, Brian Tseng, Charles Gubser, David Glass
  • Patent number: 9815901
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Publication number: 20170306416
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishnek Garg, David Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox